Proteocyte AI

Proteocyte AI A Canadian molecular diagnostics company with a novel technology that determines the risk of a head

Better cancer diagnostics

Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.

Go Beyond ConventionalPathology with STRATICYTE®.The biopsy is already there – opportunity for deeper insight is too.STR...
09/08/2026

Go Beyond ConventionalPathology with STRATICYTE®.

The biopsy is already there – opportunity for deeper insight is too.

STRATICYTE® uses a patient’s existing biopsy specimen for an objective, personalized 5-year OSCC risk, to help guide surveillance, intervention, and treatment planning.

✔ Use existing biopsy
✔ Personalized 5-year OSCC Risk Score
✔ Objective risk stratification

Learn how STRATICYTE® can help improve OPMD care and outcomes.
👉 https://proteocyte.com/straticyte/


Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Oral Health Foundation SurgeOn Events

Spot It. Test It.If you or your doctor notice an oral lesion, knowing your individual risk can help you & your healthcar...
09/01/2026

Spot It. Test It.

If you or your doctor notice an oral lesion, knowing your individual risk can help you & your healthcare provider make informed decisions about what comes next.

STRATICYTE’s® personalized 5-year Oral Cancer Risk Score uses your existing tissue sample for testing — no additional biopsy needed.

For Precision. For Peace of Mind.

Ask your healthcare provider about STRATICYTE®. Learn more:
👉 https://proteocyte.com/straticyte/patients/


American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

Not every oral potentially malignant disorder (OPMD) carries the same risk.STRATICYTE® provides an objective, personaliz...
08/25/2026

Not every oral potentially malignant disorder (OPMD) carries the same risk.

STRATICYTE® provides an objective, personalized 5-year oral cancer risk score, helping clinicians identify patients who may benefit from closer surveillance while supporting more appropriate management of lower-risk lesions.

More clarity. More confidence. Better patient care.

Learn more:
👉 https://proteocyte.com/straticyte/


American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

Integrating STRATICYTE® into your clinical workflow is simple.Your role is simple: Order the Test by completing the Test...
08/20/2026

Integrating STRATICYTE® into your clinical workflow is simple.

Your role is simple: Order the Test by completing the Test Request Form (TRF)- https://proteocyte.com/ordering-options/

Our Role: Proteocyte AI contacts the pathology lab where the original biopsy tissue resides to request tissue samples from the original specimen – NO EXTRA BIOPSY REQUIRED

Using the existing biopsy specimen, our team performs advanced biomarker analysis and digital pathology to generate a personalized 5-year oral cancer risk assessment.

No additional surgery. No added complexity.

Just the insight you need to support more confident clinical decisions.

Learn more:
👉 https://proteocyte.com/straticyte/


Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

Peace of mind starts with knowing the risk.For patients diagnosed with an Oral Potentially Malignant Disorder (OPMD), un...
08/18/2026

Peace of mind starts with knowing the risk.

For patients diagnosed with an Oral Potentially Malignant Disorder (OPMD), uncertainty can be one of the most difficult parts of the journey.

STRATICYTE® helps reduce that uncertainty by providing an objective, personalized 5-year oral cancer risk score, giving clinicians and patients greater confidence when making care decisions.

Because peace of mind begins with better information.

Learn more: proteocyte.com


Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Osteology Foundation Oral Health Foundation SurgeOn Events

Traditional histopathology is an essential part of oral lesion assessment—but it doesn't always tell the full story.STRA...
08/11/2026

Traditional histopathology is an essential part of oral lesion assessment—but it doesn't always tell the full story.

STRATICYTE® supplements histology with AI-driven biomarker analysis and digital pathology, providing an objective, personalized 5-year oral cancer risk score to support more informed clinical decision-making.

✔ Objective risk assessment
✔ Personalized patient management
✔ No additional biopsy required

Learn how STRATICYTE® can support your practice:
👉 https://proteocyte.com/straticyte/


Canadian Dental Association Canadian Partnership Against Cancer Société de recherche sur le cancer / Cancer Research Society Fondation québécoise du cancer Manitoba Dental Association NB Dental Society Newfoundland and Labrador Dental Association

🧬 Why STRATICYTE®?STRATICYTE® provides clinicians with an objective, personalized 5-year oral cancer risk score to suppo...
08/06/2026

🧬 Why STRATICYTE®?

STRATICYTE® provides clinicians with an objective, personalized 5-year oral cancer risk score to support more confident patient management.

✔️ 97% Sensitivity & Negative Predictive Value
✔️ Supports decision-making beyond traditional dysplasia grading
✔️Stratifies LOW-RISK and ELEVATED-RISK patients to support clinical follow up and management

With STRATICYTE®, clinicians can better identify which patients need intervention now—and which patients can be monitored with confidence.

Learn more: proteocyte.com


American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

Recognizing where oral cancer can occur is the first step—but understanding which lesions are most likely to progress is...
08/04/2026

Recognizing where oral cancer can occur is the first step—but understanding which lesions are most likely to progress is just as important.

STRATICYTE® helps clinicians assess oral cancer risk, providing additional insight to support earlier, more informed patient management.

Earlier risk assessment can help lead to earlier intervention.

Learn more:
👉 https://proteocyte.com/straticyte/


Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

07/28/2026

Can AI help remove subjectivity from oral dysplasia assessment?

As a guest on the Everyday Oral Surgery podcast, Dr. Paras Patel, DDS, discussed the role of AI, as used in the STRATICYTE® test.

A big challenge in pathology is variability. The same lesion may be graded differently by different clinicians—or even by the same clinician on a different day.

That’s where AI has the potential to make an impact.

The goal isn't to replace clinical expertise—it's to enhance it with data-driven insights that help predict which lesions are most likely to transform.

At the end of the day, improving objectivity means improving confidence in clinical decision-making.

Learn more about STRATICYTE® : 👉 https://proteocyte.com/straticyte/


American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

Order STRATICYTE®. We'll do the rest.Managing patients with Oral Potentially Malignant Disorders (OPMDs) shouldn't be co...
07/23/2026

Order STRATICYTE®. We'll do the rest.

Managing patients with Oral Potentially Malignant Disorders (OPMDs) shouldn't be complicated.

Simply submit your STRATICYTE® request and Proteocyte AI will handle the process—from coordinating specimen retrieval to delivering a personalized risk assessment report.

✔️ Easy ordering process
✔️ End-to-end support
✔️ Objective 5-year oral cancer risk assessment
✔️ Results that support confident patient management

Manage your OPMD patients with ease.
👉 Learn more at proteocyte.com/ordering-options/


Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

Address

Toronto, ON
M5G1L7

Website

Alerts

Be the first to know and let us send you an email when Proteocyte AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category